Skip navigation

BioWednesday London: Assessing the Translation Potential of An Early Stage Project

18:00 - 21:00

Royal Veterinary College, 4 Royal College Street, London NW1 0TU
07 June 2017
If you would like to see a summary of the discussion, please click here.

To fully harness the productivity of a strong science and innovation research base, it is important to be able to translate the appropriate findings into commercial development and products that enable better health outcomes for patients.

Defining ‘appropriate’ relating to which projects could or should be taken forward is one of the largest challenges in translational research. Technical assessment of the project needs to be matched by a sufficiently robust commercial assessment in order to create a pathway for the envisioned product or technology to reach the market. It’s not that it isn’t great science, more often than not being great science is not the only factor that influences follow-on investment and development. 

This evening’s panel will discuss how and to what degree of certainty, one can evaluate the commercial potential of an early stage project.


- Registration

18.30 - Welcome from the Host and One Nucleus
Ken Larkin, London Bioscience Innovation Centre

18.45 - Keynote Address: Evaluating Commercial Potential
Andy Smith, ICON
Please click here to view the presentation

19.00 - Panel Discussion: Selecting the Right Projects for Translational Research

Tony Jones, One Nucleus

Tas Gohir, Royal Veterinary College
Veronique Birault, The Francis Crick Institute
Richard Butt, Apollo Therapeutics
Rick Davies, J&J Innovation
Andrew Ratcliffe, Novintum Bioscience

19.45 - Closing Remarks followed by Networking Reception

21.00 - Close

Members: free 
Non-members: £50 (plus vat) 
Academics: please contact
Title: BioWednesday London: Assessing the Translation Potential of An Early Stage Project
Start: 2017-06-07 18:00:00Z
End: 2017-06-07 21:00:00Z